Mindfulness-Based Stress Reduction for Generalized Anxiety Disorder: Systematic Review and Meta-Analysis
En palabras de los autores
Objective: To evaluate the efficacy and safety of Mindfulness-Based Stress Reduction (MBSR) for anxiety symptoms in adults with generalized anxiety disorder (GAD). Design: Systematic review and meta-analysis. Data Sources: CINAHL, Embase, MEDLINE, PsycINFO, Scopus, SocINDEX, ERIC (EBSCO), and ProQuest Dissertations & Theses Global were searched from inception to October 2025; identified trial protocols were hand-searched for subsequent reports through February 2026. Eligibility criteria for selecting studies: Randomized, non-randomized, and single-arm trials evaluating the effects of MBSR on anxiety in adults with GAD. Data extraction and synthesis: Two authors independently screened records, extracted data, and assessed risk of bias. The primary outcome was anxiety symptoms; the secondary outcome was adverse events. Random-effects meta-analyses were conducted, and certainty of evidence was assessed. Results: Of 19 included reports (16 independent samples), 8 randomized controlled trials (n=1,012) were included in the primary meta-analysis. MBSR significantly reduced anxiety symptoms vs. waitlist (Hedges' g=-0.88; 95% CI -1.57 to -0.19) and general active comparators (g=-0.85; 95% CI -1.15 to -0.54), and showed no significant difference vs. escitalopram in two linked trials (g=0.09; 95% CI -0.11 to 0.29), with fewer adverse events in the in-person trial, the only one reporting them (15% vs. 79%; number needed to treat to avoid harm=2). GRADE certainty of evidence was high for the escitalopram comparison and very low for waitlist. Conclusions: MBSR is a well-tolerated, nonpharmacologic treatment option for adults with GAD. Anxiety reductions were similar to escitalopram, with fewer adverse events; independent replication is needed. MBSR may be a viable option for patients who prefer non-pharmacological management or who cannot tolerate medication. Systematic review registration: PROSPERO CRD420251140213.
Apareció: domingo, 25 de octubre. medRxiv. Preprint, todavía sin revisión por pares.